

Department of Radiation Oncology

Monthly Research Update: February 2022

CARTI Offers New Career Resources

The new [UMSOM Center for Advanced Training and Innovation](#) (CARTI) combines previous support and educational efforts with new programs and a mission to nurture and grow an expanded cadre of biomedical and clinician scientists. The center will help to identify and facilitate access to advanced research training and research career development, with a special mission focus on professional development for underrepresented minorities and women. CARTI is designed as a hub for training in foundations of research, scientific communication, and leadership skills for success in an academic research institution. The center will work to grow the next generation of clinician/scientists and research scientists, support career development, transition promising senior fellows to junior faculty, enrich the portfolios of mid-career and senior faculty, and mentor junior faculty to research independence. Among the programs to be offered initially are expert [CARTI counselors](#), specialized [CARTI training tracks](#), [individual research career development](#), [writing and communication instruction](#), and the [fellows-to-faculty program](#). Read more about the resources that will be available and sign up for the [CARTI monthly newsletter](#).

FEBRUARY AT A GLANCE TOTALS

Clinical trials

Total enrolled	39
GCC, other	9
NRG, NCI, co-ops	7
PCG Registry	23

Grants and contracts

New awards	0
Submitted	1

Articles published	6
--------------------	---

Information for this monthly update should be provided no later than the second Wednesday of each month to Miek Segers at msegers@som.umaryland.edu. The update will be published on the second Friday of each month.

Have questions about identifying a funding source? Finding research partners across the UMB/UM campuses or at another university? Defining future research strategies? Or organizing your thoughts on (virtual) paper? Contact Nancy Knight, PhD, Director of Academic and Professional Development for the department, at nknight@umm.edu

Clinical Trial Enrollment

- 23 patients at MPTC on the **PCG Registry**.
- 4 patients at MPTC on the **Deep Thermal Therapy HUD**.
- 1 patient at MPTC on **GCC 19140**: Pilot study of laser interstitial thermal therapy followed by hypofractionated radiation therapy for treatment of recurrent gliomas.
- 1 patient at UMMC on **GCC 20138**: Laser interstitial thermal therapy followed by hypofractionated radiation therapy for treatment of newly diagnosed high-grade gliomas
- 1 patient at UCH and 2 at MPTC on **GCC 20110**: A single-arm, single-stage phase II trial of Selective Avoidance of nodal VolumEs at minimal Risk (SAVER) in the contralateral neck of patients with p16-positive oropharynx cancer
- 1 patient at BWMC and 1 at Eastern Shore on **NRG GU005**: Stereotactic body radiation therapy or intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer
- 1 patient enrolled at MPTC on **PCG BRE-007**: Phase II protocol of proton therapy for partial breast irradiation in early-stage breast cancer
- 1 patient enrolled at MPTC on **NRG-HN005**: A randomized phase II/III trial of de-intensified radiation therapy for patients with early-stage, p16-positive, non-smoking associated oropharyngeal cancer
- 1 patient enrolled at MPTC on **NRG-GU002**: Phase II-III trial of adjuvant radiotherapy and androgen deprivation following radical prostatectomy with or without adjuvant docetaxel
- 1 patient enrolled at MPTC on **RTOG 1308**: Phase III randomized trial comparing overall survival after photon versus proton chemoradiotherapy for inoperable stage II-IIIB NSCLC
- 1 patient enrolled at MPTC on **GCC 1940**: A prospective comparative study of outcomes with proton and photon radiation in prostate cancer (COMPPARE) – proton randomized standard vs. hypofractionated RT

Grants and Contracts

Submitted:

France Carrier, PhD (PI), subcontract to Humanetics Corp (Prime PI Michael Kaytor, PhD) on NIAID RFA-AI-21-068 Development of Microbiome-Related Approaches for Diagnosis/ Mitigation/Treatment of Radiation Injuries (U01), for “A study of the microbiome and DEARE-lung and GI-ARS outcomes in mice treated with BIO 300” (\$737,103;5 years).

Articles Published

Entered into PubMed February 11–March 9. Titles link to PubMed abstracts, where full-text links are available.

1. Atwood TF, **Lamichhane N**, Howell K, Weiss SE, Bird L, Pearson C, Joiner MC, Dominello MM, Burmeister J. [Three discipline collaborative radiation therapy \(3DCRT\) special debate: A physicist's time is better spent in direct patient/provider interaction than in the patient's chart.](#) *J Appl Clin Med Phys*. 2022 Feb 15:e13559. Online ahead of print.
2. Mayr NA, Snider JW, **Regine WF**, Mohiuddin M, Hippe DS, Peñagaricano J, Mohiuddin M, Kudrimoti MR, Zhang H, Limoli CL, Le QT, Simone CB 2nd. [An international consensus on the design of prospective clinical-translational trials in spatially fractionated radiation therapy.](#) *Adv Radiat Oncol*. 2021 Dec 11;7(2):100866. eCollection 2022 Mar-Apr.
3. Mumtaz AA, Fischer A, Lutfi F, Matsumoto LR, Atanackovic D, Kolanci ET, **Hankey KG**, Hardy NM, Yared JA, Kocoglu MH, Rapoport AP, Dahiya S, Li AS, Brem Sunshine S. [Ocular adverse events associated with chimeric antigen receptor T-cell therapy: A case series and review.](#) *Br J Ophthalmol*. 2022 Feb 10;bjophthalmol-2021-320814. Online ahead of print.
4. Musunuru HB, Pifer PM, **Mohindra P**, Albuquerque K, Beriwal S. [Advances in management of locally advanced cervical cancer.](#) *Indian J Med Res*. 2022 Feb 10. Online ahead of print.
5. Nasser NJ, Sun K, Scanlon KM, **Mishra MV, Molitoris JK**. [Administering docetaxel for metastatic hormone-sensitive prostate cancer 1-6 days compared to more than 14 days after the start of LHRH agonist is associated with better clinical outcomes due to androgen flare.](#) *Cancers (Basel)*. 2022 Feb 9;14(4):864.
6. Haffty B, Shah C, **Mohindra P**. [A look ahead at the radiation oncology workforce in the United States, a report from the American Society for Radiation Oncology Workforce Task Force.](#) *ASTRO Blog*, March 1, 2022.

Important Dates for Upcoming Funding Submissions

Below is an updated calendar with firm due dates for upcoming major NIH deadlines in 2022 (individual RFA/PA dates may differ). Contact the Department Office of Research Administration (DORA) (msegers@som.umaryland.edu) ASAP if you plan to submit any funding proposal, regardless of funder. Failure to meet these deadlines may result in delaying your submission until the next cycle (if available).

NIH deadline	DORA budget, prelim materials	Dean/SOM prelim materials	FINAL Dean/SOM/SPA
R01 new 6/5/22	05/23/22	05/26/22	05/30/22
R21 new 6/16/22	06/03/22	06/07/22	06/09/22
R01 resub 7/5/22	06/20/22	06/23/22	06/27/22
R21 resub 7/16/22	07/01/22	07/07/22	07/11/22

Our Achievements in the SOM News and Buzz

How is information on publications and productivity sent to the *SOM News and Buzz*? Faculty members should send e-mails on recent publications, presentations, and honors to nknight@umm.edu. Each faculty name is also looked up in PubMed to identify new publications. Research administration provides data on grants and contracts. This information is reformatted per SOM requirements and sent on the second Friday of each month to *SOM News and Buzz* staff, where a small selection of items is chosen for inclusion. Items often appear several months after being forwarded from our department.